Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
17 avr. 2023 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
17 avr. 2023 06h30 HE
|
Vaxcyte, Inc.
-- VAX-24 Showed Robust Immune Responses Across all 24 Serotypes (ST) at All Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 -- -- VAX-24 2.2mcg Dose Met Opsonophagocytic Activity (OPA)...
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
16 avr. 2023 17h00 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
30 mars 2023 08h30 HE
|
Vaxcyte, Inc.
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by 2025 -- -- The Nine Incremental Serotypes in VAX-24 Cover an Additional 20-25...
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
27 févr. 2023 16h01 HE
|
Vaxcyte, Inc.
-- Company Received U.S. Food and Drug Administration (FDA) Clearance of VAX-24 Infant Investigational New Drug (IND) Application and Expects to Initiate Phase 2 Study in Second Quarter 2023 -- --...
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
21 févr. 2023 08h30 HE
|
Vaxcyte, Inc.
-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2...
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
16 févr. 2023 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
07 févr. 2023 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
05 janv. 2023 08h30 HE
|
Vaxcyte, Inc.
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest...
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
07 nov. 2022 16h10 HE
|
Vaxcyte, Inc.
-- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive...